Strategic Financing VPS has secured multiple funding milestones including a $2M government grant and smaller grants, indicating strong interest from public funding sources and potential for co-investment opportunities to expand manufacturing and clinical validation for the VP.S ENCORE system.

FDA Breakthrough The VP.S ENCORE device holds FDA breakthrough designation since 2021, signaling a unique value proposition in heart preservation technology and opportunities to engage with health systems seeking cutting-edge solutions ahead of standard practice in organ transplantation.

Academic & Research Ties Active partnerships and research funding with organizations like Texas Organ Sharing Alliance and SWPDC showcase a pathway for pilot programs, early adopters, and joint development projects to validate performance in real-world settings.

Expansion & Growth Interim leadership appointment and ongoing preclinical testing across multiple heart models suggest readiness for scale, ideal for targeted outreach to transplant centers, OEM collaborations, and distribution partners to accelerate adoption.

Cost-Effective Advantage Positioning as a simpler, accessible, and lower-cost alternative to conventional preservation methods presents a compelling value proposition for hospitals and organ procurement organizations prioritizing improved outcomes with manageable total cost of ownership.